Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for cancer.
Senti Biosciences has raised $10.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in May 2026.
Senti Biosciences's investors include Menlo Ventures, Pear VC, Lux Capital, Matrix Partners China, Gaingels.
Senti Biosciences is headquartered in South San Francisco, United States.
Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for cancer.
Senti Biosciences is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Senti Biosciences — Funding & Investors." VCBacked, May 14, 2026, https://www.vcbacked.co/company/senti-biosciences. Accessed July 19, 2026.
VCBacked. (2026). Senti Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/senti-biosciences
{{cite web |title=Senti Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/senti-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated